secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2022-04-07T23:59:59+00:00
Accession:  0001193125-22-099044
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics enters $15M upfront license deal with Jazz for WTX-613 (IFNα INDUKINE)
--------------------------------------------------------------------------------

- Upfront payment of $15M within 10 days of signing; Jazz to reimburse pre-clinical costs.
- Eligible for up to $520M in development/regulatory milestones and up to $740M in sales-based milestones.
- Tiered mid-single-digit royalties on annual net sales of licensed products.
- Werewolf grants Jazz worldwide exclusive license to patent rights for IFNα variants, including WTX-613.
- Jazz responsible for IND submission and all subsequent development and commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000119312522099044/0001193125-22-099044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000119312522099044/d335484d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-099044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer